These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9546479)

  • 1. Thromboprophylaxis and death after total hip replacement.
    Warwick D
    J Bone Joint Surg Br; 1998 Mar; 80(2):370-1. PubMed ID: 9546479
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of clinical pulmonary embolism after joint surgery in patients receiving low-molecular-weight heparin prophylaxis in hospital: a 10-year prospective register of 3,954 patients.
    Dahl OE; Gudmundsen TE; Bjørnarå BT; Solheim DM
    Acta Orthop Scand; 2003 Jun; 74(3):299-304. PubMed ID: 12899550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry.
    Jameson SS; Charman SC; Gregg PJ; Reed MR; van der Meulen JH
    J Bone Joint Surg Br; 2011 Nov; 93(11):1465-70. PubMed ID: 22058295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboprophylaxis and death after total hip replacement.
    Amstutz HC; Dorey F
    J Bone Joint Surg Br; 1997 Nov; 79(6):1037-8. PubMed ID: 9393928
    [No Abstract]   [Full Text] [Related]  

  • 6. Fondaparinux: new preparation. No better than LMWH in preventing pulmonary embolism.
    Prescrire Int; 2003 Feb; 12(63):3-5. PubMed ID: 12602371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DVT prophylaxis: better living through chemistry: affirms.
    Pellegrini VD
    Orthopedics; 2010 Sep; 33(9):642. PubMed ID: 20839678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens.
    Poultsides LA; Gonzalez Della Valle A; Memtsoudis SG; Ma Y; Roberts T; Sharrock N; Salvati E
    J Bone Joint Surg Br; 2012 Jan; 94(1):113-21. PubMed ID: 22219258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Internist patients are strongly thrombosis endangered. CERTIFY study has arrived].
    MMW Fortschr Med; 2007 May; 149(20):52-3. PubMed ID: 18051966
    [No Abstract]   [Full Text] [Related]  

  • 10. Factors associated with thromboprophylaxis for orthopedic patients and their impact on outcome.
    Muntz JE; O'Connor PJ; Yin H; Vogenberg FR
    Am J Orthop (Belle Mead NJ); 2007 Apr; 36(4):193-7. PubMed ID: 17515185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New oral anticoagulants for thromboprophylaxis after total hip or knee arthroplasty.
    Friedman RJ
    Orthopedics; 2009 Dec; 32(12 Suppl):79-84. PubMed ID: 20201481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The management of thrombosis in pregnancy: role of low-molecular-weight heparin.
    Kher A; Bauersachs R; Nielsen JD
    Thromb Haemost; 2007 Apr; 97(4):505-13. PubMed ID: 17393011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboprophylaxis practice patterns in two Western Australian teaching hospitals.
    Eikelboom JW; Mazzarol A; Quinlan DJ; Beaver R; Williamson J; Yi Q; Hankey GJ;
    Haematologica; 2004 May; 89(5):586-93. PubMed ID: 15136222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-molecular weight heparin as prophylaxis against thromboembolism after total hip replacement--is it worth the price?
    Persson BM
    Acta Orthop Scand; 2000 Apr; 71(2):215-6. PubMed ID: 10852334
    [No Abstract]   [Full Text] [Related]  

  • 16. [Prevention of thrombosis in hip alloplasty].
    Borris LC; Petersen MB; Lassen MR
    Ugeskr Laeger; 2001 Feb; 163(7):934; discussion 934-5. PubMed ID: 11228793
    [No Abstract]   [Full Text] [Related]  

  • 17. The incidence of fatal pulmonary embolism after primary hip and knee replacement in a consecutive series of 4253 patients.
    Cusick LA; Beverland DE
    J Bone Joint Surg Br; 2009 May; 91(5):645-8. PubMed ID: 19407300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Standard prevention of thrombosis in hip and knee alloplasties].
    Thomsen PB
    Ugeskr Laeger; 2001 Feb; 163(7):937-8. PubMed ID: 11228795
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?].
    Nielsen JD
    Ugeskr Laeger; 2005 May; 167(21):2261-5. PubMed ID: 15962850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.